|
- Press Release Details
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments
- NewAmsterdam Pharma Reports Positive Topline Data of Alzheimer Agent . . .
Prespecified analyses showed that obicetrapib significantly reduced primary outcome measure of Alzheimer disease biomarkers in both the overall population and APOE4 carriers said in a statement 1 “When viewed alongside the totality of evidence generated to date, including improvements in LDL-C, small LDL News Release NewAmsterdam
- Obicetrapib Hits Target in Phase 3 BROOKLYN Trial for HeFH - HCP Live
Use of obicetrapib was associated with statistically significant reductions in LDL-C when added to maximally tolerated lipid modifying therapies in patients with heterozygous familial hypercholesterolemia (HeFH), according to topline results of the phase 3 BROOKLYN trial
- ESC 2024: Obicetrapib – a promising breakthrough for dyslipidemia . . .
The completion of the Phase III TANDEM trial enrollment is a step towards the potential launch of obicetrapib, bringing NewAmsterdam closer to providing a new treatment option for heterozygous familial hypercholesterolemia (HeFH) and or atherosclerotic cardiovascular disease (ASCVD)
- NewAmsterdam Pharma to Present New Clinical and Preclinical . . . - Nasdaq
Title: Fixed-Dose Combination of Obicetrapib and Ezetimibe for LDL-C Reduction: A Phase 3 Randomized Trial Session Name: Late Breaker Session: Clinical Oral Presentation Date and Time:
- NewAmsterdam Pharma Announces Initial Data from Phase 2a - GlobeNewswire
Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments The Company believes that obicetrapib has the
- Obicetrapib patents and clinical trials: Drug pipeline profiles for . . .
When is the expected launch date for obicetrapib? A successful launch of obicetrapib is anticipated in 2027, pending positive trial outcomes and regulatory approval What are the potential risks and challenges for obicetrapib?
- Topline Results of BROADWAY Clinical Trial Sub-study | alz. org
CHICAGO, June 9, 2025 — On Monday, June 9, NewAmsterdam Pharma Company announced positive results from an Alzheimer’s disease blood biomarkers sub-study of the 52-week Phase 3 BROADWAY clinical trial of its LDL cholesterol lowering drug, obicetrapib
|
|
|